When domestic companies will win patent suits over ‘Revlimid’?
Domestic pharmaceutical companies have filed patent suits to preoccupy the market of the multiple myeloma therapy whose substance patent will be expired next year, ‘Revlimid,’ but they continued failure.
Celgene’s Revlimid(generic name: lenalidomide) is a leading company in the multiple myelom...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
